Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 288

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 288
---
 The notice generally provides that if a publicly traded U.S. corporation completely liquidates and dissolves, distributions in such complete liquidation and other distributions by such corporation in the same taxable year in which the final distribution in complete liquidation and dissolution is made are not subject to the excise tax. On June 28, 2024, the Treasury finalized certain of the proposed regulations (those relating to procedures for reporting and paying the Excise Tax). The remaining regulations (largely relating to the computation of the Excise Tax) remain in proposed form. The Treasury intends to finalize these proposed regulations at a later date and, until such time, taxpayers may continue to rely on the proposed regulations. For the redemption that occurred on September 7, 2023, the Company incurred an excise tax of $ 103,587, calculated as 1% of the fair market value of the shares redeemed on September 7, 2023. As of March 31, 2025, the excise tax associated with the September 7, 2023 redemptions had yet to be paid. As such, the Company has recorded $ 43,867as an accrual for interest and penalties associated with the unpaid excise taxes. The interest and penalties associated with the unpaid excise taxes are included within excise tax payable in the accompanying unaudited condensed balance sheets. For the redemption that occurred on March 7, 2024, the Company incurred an excise tax of $ 12,657, calculated as 1% of the fair market value of the shares redeemed on March 7, 2024. For the redemption that occurred on September 5, 2024, the Company incurred an excise tax of $ 5,372, calculated as 1% of the fair market value of the shares redeemed on September 5, 2024. For the redemption that occurred on December 20, 2024, the Company incurred an excise tax of $ 7,392, calculated as 1% of the fair market value of the shares redeemed on December 20, 2024.

<div align='center'>F-66</div>

For the redemption that occurred on March 4, 2025, the Company incurred an excise tax of $ 7,024, calculated as 1% of the fair market value of the shares redeemed on March 4, 2025. As of March 31, 2025 and December 31, 2024,